En Carta Diagnostics secures €1.5M to advance diagnostic kit platform for early Lyme disease detection

Groundbreaking patented molecular diagnostic kit poised to provide game-changing autonomous Lyme detection in minutes

27-May-2024 - En Carta Diagnostics, a deeptech start-up developing rapid Point-of-Care (POC) molecular diagnostics kits, announces €1.5M ($1.63M) in pre-seed funding. This investment will enable En Carta to make a substantial leap forward in achieving preclinical data on a prototype diagnostic kit for its ...

NovAliX and Max Planck join forces to advance Cryo-EM driven drug discovery

Collaboration will make vital process of translating scientific research and academic insights into real therapies more efficient and more effective

07-Mar-2024 - NovAliX, a specialized Contract Research Organization dedicated to enabling drug discovery, announces its long-term strategic partnership with the Max Planck Institute (MPI) for Multidisciplinary Sciences in Göttingen. Through this collaboration, NovAliX and the MPI aim to make the vital process ...

Covalab invests more than €1 million in bioproduction operations for antibodies for Covid-19 diagnostics

Company’s BioDiaThera project received almost €500,000 in subsidies as part of French ‘Capacity Building’ scheme

25-May-2022 - Covalab, a biotechnology company that specializes in the development and production of recombinant proteins and antibodies for diagnostics and therapeutics, announces that its BioDiaThera project has been awarded €491,152 ($520k) in funding as part of the French ‘Capacity Building’ scheme; part ...

Customized coating designs against resistant bacteria and viruses, including SARS-CoV-2

Spartha Medical receives €2.4M in financing from European Innovation Council

01-Feb-2022 - Spartha Medical, a French medtech start-up specialized in developing multifunctional antimicrobial, antiviral and anti-inflammatory coatings, announces it has received €2.4M ($2.75M) in grants and an additional undisclosed equity financing from the European Innovation Council (EIC) Fund. Spartha ...

Vésale Bioscience named most innovative start-up in life sciences in Europe

The Belgian start-up is developing an effective and reproducible phage therapy approach that offers a personalized solution to the major issue of AntiMicrobial Resistance

13-Dec-2021 - Vésale Bioscience, a biotech company specializing in phage therapy, with a particular focus on research into alternative solutions to antibiotics and the development of treatments for multidrug-resistant infections, announced that it has been awarded the prize for most innovative start-up in life ...

German-based startup attracts venture funding to address ‘Agitation/Aggression’ in Alzheimer’s disease

Exciva raises €9 million in Series A round

02-Nov-2021 - Exciva GmbH, a clinical biotech startup developing a novel therapeutic compound for treating agitation/aggression in Alzheimer’s disease, announces the closing of a Series A financing of €9 million ($10M) led by Andera Partners. LBBW Venture Capital and Cure8 also participated in the round. This ...

Domain Therapeutics is granted European and US patent for biosensors assessing GPCR trafficking

05-Feb-2020 - Domain Therapeutics announced that it has been granted a patent in the US and in Europecovering a novel family of biosensors. The patent, entitled ‘Biosensors for monitoring biomolecule localization and trafficking in cells’, was initially filed by Prof. Michel Bouvier and his team and is part ...

Citoxlab acquires Solvo Biotechnology

14-Mar-2018 - Citoxlab Group announced that it has entered into a definitive agreement to acquire Solvo Biotechnology. The closing of this operation will take place within the next month. Financial details were not disclosed. Through this new acquisitionCitoxlab reinforces its position in the non-clinical CRO ...

Ferrer successfully completes second phase III clinical trial in adult and paediatric patients with impetigo for antibacterial Ozenoxacin

04-Aug-2015 - Ferrer announces that it has successfully completed a second phase III clinical trial in adult and paediatric patients aged two months and older with impetigo, utilizing Ozenoxacin 1% cream as a topical treatment for dermatological infectious conditions.The study demonstrated the superiority of ...

Novasep invests €10M to reinforce its bioconjugation services

30-Jun-2015 - Novasep announces it will build a fully integrated Antibody Drug Conjugate (ADC) facility at its Le Mans site in France. The new facility will enable Novasep to complement its current ADC offering with full bio-conjugation services to meet increasing market demand. The facility is planned to be ...